Wolfe upgrades Inspire on ‘surprise’ Medicare reimbursement raise

Wolfe Research upgraded Inspire Medical (INSP) to Outperform from Peer Perform with an $180 price target The firm says the “surprise” 50% Medicare reimbursement raise “pumps oxygen” into the stock’s bull case. Inspire has already de-risked 2026 estimates, its 2025 “launch snafus” are nearly behind the company and it has “long list of potential acquirers,” the analyst tells investors in a research note. Paying revenue-times estimated 2026 revenue, which the price target represents, it “not crazy” for a SMID-cap medical technology stock, contends Wolfe. Inspire Medical shares in premarket trading are up $1.71 to $119.00.